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Abstract
Background: The metastatic ability of tumor cells is determined by level of expression of specific
genes that may be identified with the aid of cDNA microarray containing thousands of genes and
can be used to establish the expression profile of disease related genes in complex biological
system.
Materials and Methods: Salivary adenoid cystic carcinoma cell line and its high metastases
adenoid cystic carcinoma clone were used as model systems to reveal the gene expression
alteration related to metastasis mechanism by cDNA microarray analysis. The correlation of
metastatic phenotypic changes and expression levels of 4 selected genes (encoding CD98, L6,
RPL29, and TSH) were further validated by using RT-PCR analysis of human tumor specimens from
primary adenoid cystic carcinoma and corresponding metastasis lymph nodes.
Results: Of the 7,675 clones of known genes and expressed sequence tags (ESTs) that were
analyzed, 30 showed significantly different (minimum 3 fold) expression levels in two cell lines. Out
of 30 genes found differentially expressed, 18 were up regulated (with ratio more than 3) and 12
down regulated (with ratio less than 1/3).
Conclusion: Some of these genes are known to be involved in human tumor antigen, immune
surveillance, adhesion, cell signaling pathway and growth control. It is suggested that the microarray
in combination with a relevant analysis facilitates rapid and simultaneous identification of multiple
genes of interests and in this study it provided a profound clue to screen candidate targets for early
diagnosis and intervention.
Background
Adenoid cystic carcinoma (ACC) of the salivary gland is
characterized by a prolonged clinical course, high rate of
local recurrence and the delayed onset of distant
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hematogenous metastases. Late distant metastases and
local recurrences are responsible for a rather low long-
term survival rate and poor treatment results [1]. How-
ever, the molecular mechanism behind the metastasis
development is poorly understood, largely because the
tumor metastasis is a complex process involving several
distinct steps such as escape from primary tumor, dissem-
ination through the circulation, lodgment in small vessels
at distinct sites, penetration of the vessel wall and growth
in the new site as a secondary tumor [2]. A possible break-
through in understanding of tumor metastasis has
emerged with the combination of a putative hypothesis
and the development of high throughput cDNA microar-
ray technology. It is hypothesized that the long-term
development of metastasis induces genetic alteration and
subpopulation of cancerous cells that characterize the
metastatic cells with specific gene expression involved in
temporal and spatial procession of metastasis [3]. On the
other hand, examination of large-scale expression altera-
tion of specific genes involved in tumor metastasis is
made feasible by the recently developed cDNA microarray
technology that allows the simultaneous analysis of the
expression levels of thousands of genes [4].
Consistent with the above view, in this study, we used
cDNA microarray technique to examine the differences in
the gene expression profiles between a salivary adenoid
cystic carcinoma cell line ACC-2 and a highly metastatic
salivary adenoid cystic carcinoma clone ACC-M, which
was screened from ACC-2 by combination of in vivo selec-
tion and cloning in vitro [5]. Since ACC-2 and ACC-M
share identical genetic background except for different
metastatic behavior, it is presumed that the differentially
expressed genes ACC-2 and ACC-M as metastasis related
genes, which play direct or indirect roles in the progres-
sion of metastasis. The results of the cDNA microarray
analysis were further conformed by RT-PCR to determine
the expression level of specific mRNA in the primary
tumors and corresponding metastasis lymph nodes. Such
a survey not only furthers an insight into the underlying
mechanism of the adenoid cystic carcinoma metastasis,
but also helps identify candidate marker for diagnosis and
prognosis of ACC and molecular targets for metastasis
intervention.
Materials and Methods
Cell lines and specimens
Cell lines ACC-2 and clone ACC-M were previously estab-
lished in the tumor biology laboratory of Shanghai Ninth
Hospital in Shanghai Second Medical University. Cell line
ACC-2 was derived from surgically excised primary tumor
tissue from a histologically diagnosed patient with ade-
noid cystic carcinoma of the palate. The microscopic fea-
tures of the tumor showed a dominantly solid pattern of
ACC. The patient did not receive any therapy before sur-
gery. High pulmonary metastases clone ACC-M was
selected from cell line ACC-2 after five repeated selection
in vivo combined with an in vitro cloning technique and
analysis of platelet aggregation activity [6].
Cells were cultured at 37°C in 5% CO2 humidified incu-
bator in RPMI 1640 medium supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 1% penicillin
and streptomycin.
Four pairs of fresh human specimens from the same
patient were included in the RT-PCR analysis. In each pair,
one specimen was from primary tumor tissue and the
other from metastatic lymph node. Both of them were
confirmed by histological examination. All specimens
were collected after obtaining the informed consent from
the patients. Tissues were frozen at -80°C immediately
after separation, till analysis.
Total RNA extraction and mRNA isolation
Cells were grown to 80% confluence in culture bottles,
and total RNA was extracted using standard Trizol reagent
(Life Technologies, Gaitherbur, MD) following the manu-
facturer's protocol. Briefly, cells were first homogenized in
Trizol solution and incubated for 20 minutes on ice, and
then a 1/5 volume of chloroform was added to the
homogenates. After vigorous agitation for 5 minutes, the
inorganic phase was separated by centrifugation at 12000
g for 15 min at 4°C. RNA was then precipitated in one vol-
ume of isopropanol and centrifuged at 10000 g for 20
minutes at 4°C. RNA pellets were washed with 70% ice-
cold ethanol and then dissolved in diethyl pyrocarbonate
(DEPC)-treated H2O. The amount and quality of total
RNA were checked by electrophoresis on a 0.8% formal-
dehyde agarose gel. Then the polyA mRNA was purified
using the Oligotex poly (dT) resin® (Qiagen, German)
according to the manufacturer's instruction.
Synthesis and purification of labeled cDNA probe
1–2µg purified mRNA was labeled in reverse transcription
using M-MLV reverse transcriptase (Promega, Madison,
USA) in the presence of Easytides deoxyadenosin 5' tri-
phosphate [alpha-33P] (NEN® Life Science Product, Bos-
ton, USA). Before labeling, total RNA was treated with
DNase (Boehringer Mannheim, Germany) and RNasin
(Promega, Madison, USA) at 37°C for 15 minutes to
remove contaminated DNA. For each labeling, the treated
RNA was first incubated with 5 µl oligo dT (Life technolo-
gies, USA) at 70°C for 10 min. Then 6 µl 0 5× first strand
reaction buffer, 1 µl 0.1 M DTT, 1.5 µl dNTP mixture con-
taining dATP, dGTP and dTTP at 20 Um (Promega, USA),
10 µl alpha-33P dCTP and 1.5 µl superscript reverse tran-
scriptase were added and incubated at 37°C for 90 min.
The labeled first strand cDNA probes were purified byWorld Journal of Surgical Oncology 2003, 1 http://www.wjso.com/content/1/1/28
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spin column (Clontech, CA) to remove the unincorpo-
rated nucleotides.
cDNA microarray preparation
Human cDNA clones picked from cDNA libraries were
terminal sequenced. A cDNA array was assembled with a
total of 7675 cDNA clones representing the same number
of independent cDNA clusters. All cDNA fragments were
amplified by PCR and verified by gel electrophoresis. PCR
products were spotted onto two 8 × 12 cm Hybond®-N
nylon membranes (Amersham Pharmacia, Buckingham-
shire, UK) using an arrayer (BioRobotics, Cambridge,
United Kingdom). Each spot carried ~100 nl in volume
and was 0.4 mm in diameter, and each cDNA fragment
was placed in two different spots (double-offset). Eight
housekeeping genes encoding ribosomal protein S9
(RPS9),  β-actin (ACTB), glyceraldehyde-3-phosphate
dehydrogenase, hypoxanthine phosphoribosyltransferase
1, Mr 23,000 highly basic protein (RPL13A), ubiquitin C,
phospholipase A2, and ubiquitin thiolesterase (UCHL1)
were spotted and evenly distributed as hybridization
intra-membrane control, each in 12 places. Hybridization
data was considered invalid if among the 12 spots repre-
senting the same gene, the intensity of the darkest spot
exceeded 1.5-fold of that of the weakest spot.
Hybridization and image analysis
Prepared nylon membranes were prehybridized in 20 ml
of prehybridization solution (6×SSC, 0.5% SDS, 5×Den-
hardt's, and 100 µg/ml denatured salmon sperm DNA) at
68°C for 3 hours. Overnight hybridization with the 33P-
labeled cDNA in 6 ml of hybridization solution (6×SSC,
0.5% SDS, and 100 µg/ml salmon sperm DNA) was fol-
lowed by stringent washing (0.1×SSC, 0.5% SDS, at 65°C
for 1 h). Membranes were exposed to phosphor screen
overnight and scanned using an FLA-3000A Plate/Fluores-
cent Image Analyzer (Fuji Photo Film, Tokyo, Japan).
Radioactive intensity of each spot was linearly digitalized
to 65,536 gray-grades in a pixel size of 50 µm in an image
reader and recorded using the Array gauge software (Fuji
Photo Film, Tokyo, Japan). After subtraction of back-
ground chosen from an area where no cDNA was spotted,
genes with intensities >10 were considered as positive sig-
nals to ensure that they were distinguished from back-
ground with statistical significance >99.9%.
Normalization among arrays was based on the sum of
background-subtracted signals from all genes on the
membrane. On the basis of each gene's ratio of expression
level between the ACC-M and ACC-2(ACC-M/ACC-2), we
divided those with significantly differential expression
into two classes: up-regulated with the ratio over 3.0,
down-regulated with the ratio below 1/3.
Semi-quantitative RT-PCR
Four selected genes, CD98, L6, RPL29, and TSH, were
selected and investigated in this study to evaluate the dif-
ference of expression of them between primary ACC
tumor tissue and ACC metastasis lymph node in vivo,
thus confirming the reliability of our approach. 1 µg each
of total RNA from 4 primary tumor tissue samples and 4
corresponding metastasis lymph node tissue samples
were used as templates in a total volume of 20 µl reverse
transcription reaction system. The cDNA were then trans-
ferred to a PCR master mixture containing 1×PCR Buffer,
1.8 mM MgCl2, and 2.5 units of Taq polymerase, 1 µM
gene specific primers, as listed in Table 1. Primers were
designed using the Primer3 program in the Center for
Genome Research at the Whitehead Institute http://www-
genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi. To
avoid problems associated with genomic DNA contami-
nation primers were made to span an intron. PCR condi-
tions were as follows: 1 cycle of 95°C for 10 minutes, 25–
30 cycles of 95°C for 1 minute, 60°C for 1 minute, and
72°C for 1 minute, and final extension at 72°C for 5 min-
utes after the last cycle. Amplified fragments were visual-
ized by ethidium bromide staining of the agarose gel and
photographed under UV light.
Results
Identification of genes differentially expressed between 
ACC-2 and ACC-M cells
The cDNA microarray technique was applied to analyze
the expression patterns of ACC-2 and ACC-M cells. All
tests were considered valid with the maximal variation of
hybridization intra-membrane control signal intensity
being 1.4-fold. Among relevant 7,675 genes and expressed
sequence tags (ESTs) assembled in the cDNA microarray,
30 were found differentially expressed, with the difference
signal intensity ratio of more than 3. Genes and ESTs were
divided into two groups on the basis of the difference in
signal intensity: Out of 30 differentially expressed genes
or ESTs, 18 were up-regulated (signal intensity ratio more
than 3) in ACC-M clone compared withACC-2 cell line
Table 1: Primers used for RT-PCR
Gene Primers Product size
RPL29 5'ACATGGCCAAGTCCAAGAAC3' 
5'TTAGGCCCTTTTTGTTGTGC3'
165
CD98 5'TCTTGATTGCGGGGACTAAC3' 
5'GAGCCTTGCCTGAGACAAAC3'
197
L6 5'AGGGCCAGTACCTTCTGGAT3' 
5'AAGCCACATATGCCTCCAAG3'
169
TSH 5'CGTGCCACTGCAGTACTTGT3' 
5'TTGAAGCGTGTCAAAGTGGT3'
165World Journal of Surgical Oncology 2003, 1 http://www.wjso.com/content/1/1/28
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and 12 down-regulated (signal intensity ratio less than 1/
3). Results are shown in table 2.
Semi-quantitative RT-PCR analysis
RT-PCR was performed on the primary tumor tissues and
metastasis lymph nodes to give in vivo validation to the
array results for the selected genes. The results were
revealed in electrophoresis pattern shown in Figure 1,
confirming the results of the cDNA microarray data.
Expression level in ACC metastasis lymph nodes com-
pared with ACC primary tumor tissues showed similarly
down-regulation of CD98, RPL29, TSH and L6 in all the
samples.
Discussion
Several approaches have been used to study the gene pro-
file alteration that may occur in the development of ade-
noid cystic carcinoma and metastasis [7-11]. However,
most studies were highly focused and do not provide
insight into global gene expression pattern although they
contributed greatly to our current understanding [12].
Focusing on gene expression patterns of a multitude of
genes, referred to as genetic fingerprints, is proving to be a
much more powerful approach than studying a small
number of genes that may not hold much clinical
significance individually [13]. Recently developed cDNA
microarray technology makes it possible for us to analyze
multi gene related process such as metastasis due to the
wide spectrum of genes and high throughput analysis
[14]. In this study, we have chosen human adenoid cystic
carcinoma cell lines as a model system to study changes in
gene expression that should be of importance in the
pathogenesis of metastasis. Cell lines are important tools
for in vitro studies of neoplasms, and are highly valuable
Table 2: List of the up-regulated and down-regulated genes and ESTs in the microarray
Gene bank Accession No Name Chromosomal Localization Ratio of ACC-M/ACC-2
Up-Regulated
U05861 hepatic dihydrodiol dehydrogenase 10p15-p14 5.91
D17793 KIAA0119 10p15-p14 6.47
AB007870 KIAA0410 13q12.13 3.63
X16901 RAP30 subunit 13q14 3.18
U09848 zinc finger protein LNF139 7q21.3-q22.1 4.53
X84003 TAF1118 1p13.1 3.40
D90282 carbamyl phosphate synthetase I 2q35 3.40
U40490 nicotinamide nucleotide 
transhydrogenase
5p13.1-5cen 4.25
D84488 small GTP-binding protein 1q32 3.05
D14533 XPAC protein 9q22.3 3.12
X60221 H+-ATP synthase subunit b 1p13.2 3.12
A1436789 EST ? 3.13
W05842 EST ? 3.18
AA186737 EST ? 3.05
N6482 EST ? 4.36
A1254779 EST ? 3.50
AA582554 EST ? 3.40
AA478034 EST ? 3.10
Down-Regulated
AB018010 CD98 11q13 0.22
Z49148 ribosomal protein L29 12q23.1 0.23
L13435 3p21.1 gene 3p21 0.31
U23143 mitochondriol serine 
hydroxymethyltransferase
12q12-q14 0.32
AW072071 EST ? 0.25
YO0483 gluthathione peroxidase ? 0.30
A1804930 EST ? 0.07
AJ249732 G8 protein 6p21.3 0.25
W20128 EST ? 0.32
AI005336 EST ? 0.25
S70585 thyroid-stimulating hormone 
(TSH)
6q12-q21 0.30
M90657 tumor antigen (L6) 3q21-q25 0.30World Journal of Surgical Oncology 2003, 1 http://www.wjso.com/content/1/1/28
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in studies requiring considerable amount of material [15].
On the other hand, since adenoid cystic carcinoma itself
is heterogeneous in nature, cell lines can supply a homo-
geneous cell population exempted from the disturbance
of non-parenchyma cells in ACC tumor, including stroma
cells, adipose cells, endothelial cells, and infiltrating lym-
phocytes, and give a more accurate data interpretation.
In this study, cDNA microarray analysis of cell line ACC-
2 and cell clone ACC-M revealed several differentially
expressed genes. The reliability of our approach was fur-
ther validated using RT-PCR on 4 paired specimens from
primary tumor and metastatic lymph node. The difference
of expression level of 4 selected genes disclosed by semi-
quantitative RT-PCR was consistent with the results of
cDNA microarray analysis. Among those differentially
expressed genes, some of genes were already known as
active participants related to tumor and metastasis.
CD98 is found under expressed by 4.5-fold in ACC-M
clone compared with ACC-2 in our study. CD98, a het-
erodimeric type II transmembrane glycoprotein present in
all established human cell lines and most malignant
human cells, functions in amino acid transport, cell
fusion and homotypic cell aggregation [16]. It is also an
important regulator of integrin activation and an onco-
genic protein, playing a role in integrin signaling path-
ways [17-19]. It is known that integrin is key factor for cell
invasion and migration, allowing the cancer cell to pene-
trate itself into the tissue and attach to the target tissue's
basal matrix by binding to components of the extra cellu-
lar matrix [20]. Integrin-CD98 association and relative
mechanisms to regulate cell adhesion, migration, and
metastasis have been profoundly reported recently. Zent
et al have shown that CD98 can associate with isolated
cytoplasmic portions of some β1 integrin isoforms [21].
Kolesnikova et al have recently shown that CD98 consti-
tutively and specifically associated with various β1
integrin subunits by reciprocal immunoprecipitation
experiments [12]. They propose that by cross-linking
CD98, it acts as a "molecular facilitator" in the plasma
membrane, clustering β1 integrins to form high-density
complexes, thus subsequently lead to integrin activation
and adhesion, integrin signaling, and anchorage-inde-
pendent growth. In this context, our observation of down-
regulated expression of CD98 in high metastasis cell clone
might contribute to the elucidation of suppressive role of
CD98 in molecular mechanism of metastasis although
further investigation is needed to postulate relationship of
the distribution of CD98 and the tumor-spreading pattern
and differentiation and metastatic behavior in ACC.
Ribosomal protein L29 gene (Heparin/Heparan Sulfate
Interacting Protein Gene) was shown to be down regu-
lated in high metastasis cell clone ACC-M. HIP is a cell
surface binding protein, highly expressed in most human
epithelial cell lines, including uterine and fibroblastic
cells [22]. By binding directly to heparin it functions as a
cell-cell and cell-extracellular matrix adhesion molecule
[23-26]. Recent studies suggested that HIP may play a role
in cell migration and metastasis of melanoma and breast
cancer cells [27,28]. Wang et al [29], reported Heparin/
Heparan sulfate interacting protein (HIP) to be up-regu-
lated in colorectal carcinoma, a significant inverse correla-
tion between HIP levels and the presence of distant
metastasis (Duke's stage D) was also noted. This indicated
up-regulation of HIP to be an early event in carcinogene-
sis, and its increased expression may facilitate growth.
Later in tumor progression, HIP may be down-regulated
to decreased cell adhesion, favoring metastasis. Our data
supports the concept of down-regulation of HIP in tumors
with metastasis.
Under expression of tumor-associated antigen L6 gene in
high metastatic cell clone and metastasis lymph nodes is
another finding in this report. Tumor-associated antigen
L6 is a kind of cell surface antigen that is known to express
in the lung, breast, colon, and ovarian carcinomas, medi-
ating cell to cell and cell-to matrix interaction [30].
However, other research have shown that the expression
Semi-quantitative RT-PCR analysis of selected genes Figure 1
Semi-quantitative RT-PCR analysis of selected genes. Total 
RNA isolated from 4 primary tumor tissue samples and 4 
corresponding metastasis lymph node tissue samples were 
used as a template for RT-PCR using the gene-specific prim-
ers described in Table 2. RT-PCR showing the down-regula-
tion of (A) RPL29, (B) CD98,(C)L6 and (D)TSH. (E)GAPDH 
was used as an internal reference. Pi, primary tumor; Mi, 
metastasis tumor (i refer to the number of sample).World Journal of Surgical Oncology 2003, 1 http://www.wjso.com/content/1/1/28
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level of L6 was found to increase in metastatic-tumor-
derived cells compared with primary-tumor-derived cells
[31], thus leaving the controversy open, and requiring fur-
ther investigations.
Thyroid stimulating hormone (TSH) has been reported to
be associated with enhanced tumor proliferation and
aggressiveness in follicular thyroid cancer cells [32]. Loss
of TSH stimulation allows the lung metastasis the highest
basal invasive potential [33]. Similar findings of decrease
in TSH mRNA expression level had been observed in ACC-
M cell line and metastasis lymph node, supporting the
previous report of metastasis inhibiting role of TSH [33].
Our results show that a decreased transcription of this
gene could be helpful for the tumor metastasis by
decreased cell adhesion and loss of contact inhibition
control.
It is clear from our results that high metastasis ACC cell
clone has a genome-wide genetic expression profile that
differs from primary ACC cell line. Having determined
that such differences exist, the next question is to what
extent are these gene expression alterations related to
metastasis? Or whether there is genetic expression profile
heterogeneity among tumors of a particular histopatho-
logic grade and metastatic potential? Future studies are
needed to directly compare gene expression profiles
between different samples of same stage to affirm this
possibility.
Analysis of cell lines using cDNA microarray also revealed
several novel differentially expressed genes, which have
not been previously reported to be related to tumor
metastasis, for example, TAF1118 gene, zinc finger protein
LNF139 gene, hepatic dihydrodiol dehydrogenase gene
etc. The further validation and detailed mechanism of
these genes in conferring the phenotype of high metasta-
sis to a cell need more extensive investigation. The global
molecular regulatory network would also shed a light on
our understanding of the mechanism of pathogenesis of
metastasis and potential gene therapy[34].
We report here an average 3-fold differential expression
ratio. We attribute this result to the close genetic back-
ground of the ACC-2 and ACC-M cells as they were
derived from the same parental source. ACC-2 was estab-
lished from primary adenoid cystic carcinoma and ACC-
M was screened out from ACC-2. We have set only those
genes significant whose expression was changed by at
least a factor of three. However, we think that this cutoff
point is arbitrary and that there might exist some impor-
tant enough genes whose expression changed less than a
factor of three. It is necessary to complement the prelimi-
nary cDNA microarray results with some more sensitive
confirmatory experiments for target genes. There might be
some false negative metastasis-related genes missed in this
report especially for those with signal intensity ratio less
than three. Hopefully, this technical problem could be
prevented and the overall signal intensities could be
adjusted by a newly introduced optimization strategy
called directed application of capture oligonucleotides
[35].
The measurement of gene expression can, therefore, pro-
vide information on regulatory mechanisms, biochemical
pathways, cellular control mechanisms and potential tar-
gets for intervention and therapy in a variety of disease
states [36]. Our results support the hypothesis that multi-
ple specific genes may contribute to the development of
distant metastases from adenoid cystic carcinoma cells.
cDNA microarray analysis of the model system for differ-
entially expressed gene involved in adenoid cystic carci-
noma metastasis has revealed a variety of specific genes,
including putative common metastasis-related genes,
which provides a basis for rationally determining which
pathways are appropriate for further study and which
molecular targets are potential targets for gene therapy
[37]. These findings will provide new insights to further
explore the complicated molecular events of tumor metas-
tasis. Studies of molecular mechanism regulating these
changes would help to identify prognostic marker and
treatment targets for cancer metastasis and allow more
accurate risk stratification for clinical metastases.
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